After a Kerala woman's lawsuit exposed mark-ups of up to 700%, India has capped trade margins on 137 more cancer medicines.
A drug that a hospital buys for 2,700 rupees. A patient who is charged 27,000 for it. Who pockets the difference? That gap, tenfold and perfectly legal, was read out in India's supreme court on 29 September, and the judges did not hide their anger.
They called the situation "carnage" and "extortion". The person who set all this in motion was not a lawyer or a politician. Sarojam Radhakrishnan, a retired bank employee in Kerala, was diagnosed with breast cancer in 2021. Her doctors prescribed targeted treatment, but it cost more than 63,000 rupees (about £500) a month, far beyond her family's means.
Instead of quietly giving up, she asked a court to intervene. In 2022 she filed a petition with the Kerala high court, and the case eventually climbed all the way to the top. What did the judges find? Analysis by the National Pharmaceutical Pricing Authority showed that the trade mark-up on some cancer drugs averaged 170%, and in extreme cases passed 700%.